Sopartec

BiocSol focus on sustainable microbial-based crop protection.

CISSOID S.A. is a fabless semiconductor company based in Mont Saint Guibert, Belgium, specializing in high temperature electronics. Founded in 2000, CISSOID develops integrated circuits designed to operate reliably over a wide temperature range, from -55°C to +225°C, and has tested them in conditions as extreme as -200°C to +300°C. Their product portfolio includes voltage regulators, voltage references, power switches, small signal diodes, high-voltage power modules, and various mixed-signal ICs such as analog-to-digital converters and amplifiers. These products are engineered for demanding applications in industries like oil and gas, aerospace, automotive, and industrial sectors, where they perform under harsh environmental conditions. CISSOID also offers high temperature packaging and electronic systems design services, and is recognized for its expertise in silicon-on-insulator technology, which enhances performance in extreme environments. The company serves a global market through a network of distributors and representatives across multiple regions, including Asia-Pacific, Europe, the Middle East, Africa, and the Americas.

Viridaxis SA is a biotechnology company based in Charleroi, Belgium, specializing in the development of biological solutions for horticulturalists and farmers. Founded in 2004 as a spin-off from Louvain Catholic University, the company focuses on the mass production of beneficial insects, particularly parasitoids, to combat crop pests. Utilizing innovative technology, Viridaxis produces environmentally friendly products that serve as alternatives to toxic insecticides, employing biopolymer capsules filled with powdered crustacean and algae extracts. The company supplies its products to both Belgian and multinational companies in the agricultural sector, while expanding its research and development activities to enhance production capacity and develop new offerings.

Diatos is a biopharmaceutical company founded in 1999 and headquartered in Paris, France with two subsidiaries in Leuven, Belgium and in the San Francisco Bay Area, USA. Diatos is focused on the research, development and marketing of new versions of existing anti-cancer chemotherapeutic drugs with enhanced tumor targeting or improved biodistribution. Diatos has built its portfolio of drugs and drug candidates through a strategy of license acquisitions as well as an internal research and development activity based on its prodrug technologies, Vectocell® and Tumor-Selective Prodrug (TSP).